No CrossRef data available.
Article contents
Sacubitril/valsartan in paediatric cardiomyopathy: a retrospective evaluation of ventricular response and clinical outcomes
Published online by Cambridge University Press: 23 June 2026
Abstract
Background:
Sacubitril/valsartan is widely used in adults with heart failure with reduced ejection fraction, but paediatric experience, especially across ventricular dysfunction phenotypes, remains limited.
Aim:
To evaluate the efficacy and tolerability of sacubitril/valsartan in children with cardiomyopathy and compare outcomes in patients with predominantly right or left ventricular dysfunction.
Methods:
This single-centre retrospective study included 33 patients aged 1 month to 18 years who received sacubitril/valsartan between October 2020 and October 2024. Diagnoses included arrhythmogenic right ventricular cardiomyopathy, left ventricular non-compaction, and dilated cardiomyopathy. Patients were stratified by predominant ventricular dysfunction. Echocardiographic parameters, N-terminal pro B-type natriuretic peptide, six-minute walk test, NYHA class, blood pressure, creatinine, and potassium were recorded at baseline and at 1, 3, and 6 months, and at final follow-up. Clinical outcomes included rehospitalisation, death, and heart transplantation or listing.
Results:
The cohort included 21 male patients (63.6%), and the median age was 8.6 years. Arrhythmogenic right ventricular cardiomyopathy was present in 45.5%, left ventricular non-compaction in 15.2%, and dilated cardiomyopathy in 39.4%. Left ventricular ejection fraction >45% increased from 39.4% to 72.7%. Mean N-terminal pro B-type natriuretic peptide decreased from 6309 to 3137 pg/mL (p < 0.001). NYHA class improved or remained stable in 93.3% of patients, with greater improvement in left ventricular dysfunction. During a median 17.3-months follow-up, rehospitalisation occurred in 42.4%, and 5 patients died or underwent heart transplantation/listing. Hypotension occurred in 18.2% but was manageable.
Conclusion:
Sacubitril/valsartan was generally well tolerated and associated with improved ventricular function, biomarkers, and functional status in paediatric cardiomyopathy, particularly in left ventricular dysfunction.
Information
- Type
- Original Article
- Information
- Copyright
- © The Author(s), 2026. Published by Cambridge University Press
References
Heidenreich, PA, Bozkurt, B, Aguilar, D, et al. AHA/ACC/HFSA guideline for the management of heart failure. Circulation 2022; 145(18): e895–e1032.Google ScholarPubMed
McMurray, JJV, Packer, M, Desai, AS, et al. Angiotensin–Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993–1004. DOI: 10.1056/NEJMoa1409077.CrossRefGoogle ScholarPubMed
U.S. Food and Drug Administration (FDA). Approval Letter for Entresto (sacubitril/valsartan), Pediatric Supplement. March 2019. Link to Letter (PDF).Google Scholar
Kantor, PF, Abraham, JR, Dipchand, AI, et al. Pediatric heart failure: current state and future directions. Circ Heart Fail 2017; 10(12): e003396. DOI: 10.1161/CIRCHEARTFAILURE.116.003396.Google Scholar
Fudim, M, Felker, GM. Pharmacologic strategies in pediatric heart failure: extrapolation and evidence. JACC Heart Fail 2020; 8(9): 725–728. DOI: 10.1016/j.jchf.2020.06.005.Google Scholar
Heidenreich, PA, Bozkurt, B, Aguilar, D, et al. AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 2022; 79(17): e263–e421. DOI: 10.1016/j.jacc.2021.12.012.CrossRefGoogle ScholarPubMed
Arbelo, E, Protonotarios, A, Gimeno, JR, et al. ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44(37): 3503–3626. DOI: 10.1093/eurheartj/ehad194.CrossRefGoogle ScholarPubMed
Lopez, L, Colan, SD, Frommelt, PC, et al. Guidelines for performing a comprehensive pediatric transthoracic echocardiographic examination: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2010; 23(5): 465–495. DOI: 10.1016/j.echo.2010.03.019.CrossRefGoogle Scholar
Cantinotti, M, et al. Reference intervals for NT-proBNP in healthy pediatric population: data from a multicenter study. Clin Chem Lab Med 2014; 52(6): 879–885.Google Scholar
Balmforth, C, Simpson, J, Shen, L, et al. Outcomes and effect of treatment according to etiology in HFrEF: An analysis of PARADIGM-HF. JACC Heart Fail 2019; 7(10): 865–873.CrossRefGoogle ScholarPubMed
Giglia, TM, Jenkins, KJ, Vetter, VL, et al. Sacubitril/Valsartan in pediatric heart failure: a multicenter dose-finding and PK/PD study (PANORAMA-HF). J Am Coll Cardiol 2022; 79(9): 905–917.Google Scholar
Chen, X, Wu, M, Zhu, Y, et al. Real-world experience with sacubitril/valsartan in pediatric heart failure. Cardiol Young 2025; 29(9): 1079–1085.Google Scholar
Bruns, A, Slaverio-Witt, J, Pahl, E, Huh, J, Auerbach, S. Sacubitril/valsartan in children with dilated cardiomyopathy: a case series. Pediatr Cardiol 2020; 41(7): 1199–1206.Google Scholar
Tan, LE, Fang, Y, Gong, F, Chen, J, Wu, Q. Sacubitril/valsartan in pediatric patients with heart failure: clinical experience in a single center. Clin Ther 2021; 43(4): 704–715.Google Scholar
Docherty, KF, Vaduganathan, M, Solomon, SD, McMurray, JJV. Sacubitril/valsartan:Evolving evidence in HFrEF. J Am Coll Cardiol 2022; 79(7): 673–687.Google Scholar
Bayes-Genis, A, Barallat, J, Galán, A, et al. Soluble neprilysin and prognosis in heart failure with reduced ejection fraction. Eur J Heart Fail 2020; 22(4): 688–698.Google Scholar
Volpe, M. Natriuretic peptides and cardio-renal disease. Eur Heart J Suppl 2016; 18(Suppl E): E9–E13.Google Scholar
Sharifi Kia, D, Kheradvar, A. Effects of sacubitril/valsartan on cardiac structure and function in animal models. Am J Physiol Heart Circ Physiol 2020; 318(4): H916–H927.Google Scholar
Giglia, TM, Jenkins, KJ, Sleeper, LA, et al. PANORAMA-HF part 2: efficacy and safety of sacubitril/valsartan in pediatric heart failure. J Am Coll Cardiol 2022; 79(9): 905–917.Google Scholar
Jain, CC, Sharma, M, Menon, V, et al. Role of ARNI in right heart failure secondary to pulmonary hypertension. ESC Heart Fail 2023; 10(2): 1230–1241.Google Scholar
Zhao, Y, Li, X, Xu, B, et al. Sacubitril/valsartan alleviates right ventricular remodeling in pulmonary arterial hypertension. ESC Heart Fail 2023; 10(4): 2774–2784.Google Scholar
Reddy, YNV, Obokata, M, Verbrugge, FH, Lin, G, Borlaug, BA. Hemodynamic effects of sacubitril–valsartan in heart failure with preserved ejection fraction. J Am Coll Cardiol 2018; 72(4): 375–385.Google Scholar
Morales, DL, Rossano, JW, Naftel, DC, et al. Mechanical circulatory support as bridge to pediatric heart transplantation: a multicenter study. J Thorac Cardiovasc Surg 2021; 162(4): 1208–1217.Google Scholar
Wang, Y, Ma, Y, Chen, X, et al. Sacubitril/valsartan in children with heart failure: a systematic review. ESC Heart Fail 2023; 10(1): 317–328.Google Scholar
Chen, S, Zhou, Y, Li, Q, et al. Safety and efficacy of ARNI in infants with cardiomyopathy. Am J Physiol Heart Circ Physiol 2022; 323(6): H1041–H1051.Google Scholar
Lipshultz, SE, Sleeper, LA, Towbin, JA, et al. The incidence of pediatric cardiomyopathy: a study from the pediatric cardiomyopathy registry. N Engl J Med 2003; 348(17): 1647–1655.CrossRefGoogle Scholar
Singh, TP, Almond, CS, Givertz, MM. Improved outcomes in children with cardiomyopathy over time. Circulation 2019; 140(9): 733–735.Google Scholar
Rossano, JW, Kim, JJ, Decker, JA, et al. Prevalence, morbidity, and mortality of heart failure–related hospitalizations in children. J Am Coll Cardiol 2012; 59(13): 1190–1197.Google Scholar
Miyamoto, SD, Stauffer, BL, Nakano, S, et al. Sacubitril/valsartan modulates molecular remodeling in pediatric heart failure. Pediatr Cardiol 2013; 34(5): 1223–1230.Google Scholar
Alvarez, JA, Meadows, KA, Powell, AW, et al. Nutritional outcomes following heart failure therapy in children. J Heart Lung Transplant 2022; 41(7): 917–925.Google Scholar
A correction has been issued for this article:
Aslihan Karaman
[Opens in a new window]Aslihan Karaman
, Buse Günyel
[Opens in a new window]Buse Günyel
, Bahar Caran
[Opens in a new window]Bahar Caran
, Erman Cilsal
, Fatma Sevinc Sengul
, Pelin Ayyıldız
, Selman Gokalp
[Opens in a new window]Selman Gokalp
, Alper Guzeltas
[Opens in a new window]Alper Guzeltas
and Sezen Atik Ugan
[Opens in a new window]Sezen Atik Ugan
Linked content
Please note a has been issued for this article.